Dactolisib (BEZ235)

Name: Dactolisib (BEZ235)
Brand: Selleck Chemicals
SKU: S1009
Rating: 5 (375 reviews)

For research use only.

Catalog No.S1009 Synonyms: NVP-BEZ235

375 publications

CAS No. 915019-65-7

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

Selleck's Dactolisib (BEZ235) has been cited by 375 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Cell Rep, 2020, 32(12):108171

PubMed: 32966799 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E3058

PubMed: 33092134 ( click the link to review the publication )
Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3689

PubMed: 33316942 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Bioinformatics, 2020, btaa858

PubMed: 33067636 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12888

PubMed: 33338300 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9240

PubMed: 33287446 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.3432

PubMed: 32976685 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

Oncol Lett, 2020, 20(6):326

PubMed: 33123242 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )
Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1900-1918

PubMed: 32642299 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Can J Physiol Pharmacol, 2020, 10.1139/cjpp-2020-0280

PubMed: 32893666 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29926

PubMed: 32654229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):524

PubMed: 32963283 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

Elife, 2020, 9:e53367

PubMed: 32513387 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-4245

PubMed: 32605911 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):223-235

PubMed: 31776938 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11487

PubMed: 32661241 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )
Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Cell Death Differ, 2019, 26(3):548-564

PubMed: 30050055 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2019, 316(1):H61-H69

PubMed: 30359076 ( click the link to review the publication )
Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Am J Transl Res, 2019, 11(10):6534-6543

PubMed: 31737204 ( click the link to review the publication )

Am J Transl Res, 2019, 11(12):7255-7271

PubMed: 31934276 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Oncol Rep, 2019, 10.3892/or.2019.7265

PubMed: 31524277 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

PLoS One, 2019, 14(5):e0216603

PubMed: 31100067 ( click the link to review the publication )

Reprod Sci, 2019, 1933719119828067

PubMed: 30791863 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Exp Ther Med, 2019, 18(3):2278-2284

PubMed: 31410178 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

ACS Pharmacol Transl Sci, 2019,

PubMed: 32259061 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2018,

PubMed: 30224486 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )
Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10483-10496

PubMed: 29535821 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Sci Signal, 2017, 10(507)eaam7550

PubMed: 29184034 ( click the link to review the publication )

J Med Chem, 2017,

PubMed: 28471660 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Oncol, 2017, 11(9):1130-1142

PubMed: 28544747 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10612

PubMed: 28878291 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12406

PubMed: 28963527 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )
Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Cell Cycle, 2017, 16(21):2146-2155

PubMed: 28910567 ( click the link to review the publication )

Oncotarget, 2017, 8(50):88043-88058

PubMed: 29152140 ( click the link to review the publication )

Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7265-7275

PubMed: 27980219 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )
Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Biol Chem, 2016, 397(7):671-8

PubMed: 26910743 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65627-65642

PubMed: 27582537 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19214-27

PubMed: 27036037 ( click the link to review the publication )
Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

Cancer Sci, 2015,

PubMed: 25483727 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )
Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

BMC Cancer, 2015,

PubMed: 26205886 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26270481 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )
Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12862-76

PubMed: 25404640 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )
Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e827

PubMed: 24091670 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )
J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012,

PubMed: 22989520 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MnfERY51cW2rY4LvZolidCCDc4PhfS=>		MYCxPEBp	NUL2elNITE2VTx?=	NY\kc2dFSW62aYTyfZBidm:\|b33hcEBi[3Srdnn0fUB4cXSqIFXDOVAhd2ZiMD6wNFI2KM7:TR?=	MViyOFgxPTl2Nh?=
MCF7	NVfxTG95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU[wMlAyNTFyMDFOwG0>	MVW0PEBp	M1;SeGROW09?	NH;zUoNKSzVyPUCuO\|Mh\|ryP	NWC5U4I5OjN6N{G5NFQ>
HCT116	NFfmWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvJTJcyOC5yMT2xNFAh\|ryP	MUS0PEBp	NVq5NWNLTE2VTx?=	MmfXTWM2OD1zLkG2JO69VQ>?	NF3mc\|gzOzh5MUmwOC=>
U87MG	Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPENE4xOS1zMECg{txO	M1rCfFQ5KGh?	NF\rTZZFVVOR	Ml23TWM2OD1zLkOyJO69VQ>?	NXTXdJBEOjN6N{G5NFQ>
HBC4	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDPSJgxNjBzLUGwNEDPxE1?	NHXKRWk1QCCq		MUXMc4chT0l3ME2tPE43OSCP	MnjNNlI{OzZ{NE[=
BSY1	M3rrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlS5NE4xOS1zMECg{txO	NILXbWc1QCCq		NH;TeVlNd2diR1m1NF0uQC52ODDN	M1vxR\|IzOzN4MkS2
HBC5	NY\LPYNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\XSlAvODFvMUCwJO69VQ>?	NH;xXVI1QCCq		NGrmPJlNd2diR1m1NF0uPy56NzDN	MXeyNlM{PjJ2Nh?=
MCF7	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYOwMlAyNTFyMDFOwG0>	NVvoWGtLPDhiaB?=		NHTVbItNd2diR1m1NF0uQC5zNjDN	MYWyNlM{PjJ2Nh?=
MDA-MB-231	NWTKUpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvZNlk6OC5yMT2xNFAh\|ryP	MkiwOFghcA>?		M2HkfGxw\yCJSUWwQU05NjB7IF2=	MkHjNlI{OzZ{NE[=
U251	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjuc\|ZTOC5yMT2xNFAh\|ryP	MoHKOFghcA>?		Mn;hUI9oKEeLNUC9MVcvPjZiTR?=	MnrHNlI{OzZ{NE[=
SF268	NX\2elVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlW1NE4xOS1zMECg{txO	MYG0PEBp		MlTiUI9oKEeLNUC9MVcvQTJiTR?=	MnTjNlI{OzZ{NE[=
SF295	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWKwMlAyNTFyMDFOwG0>	MVm0PEBp		NEjpPG1Nd2diR1m1NF0uQC5\|MTDN	Ml;HNlI{OzZ{NE[=
SF539	NV3BTIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O0T\|AvODFvMUCwJO69VQ>?	NHrUe4w1QCCq		M2Wwemxw\yCJSUWwQU05NjV7IF2=	Mkj2NlI{OzZ{NE[=
SNB75	NY\LZpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LsPFAvODFvMUCwJO69VQ>?	MX:0PEBp		MlL3UI9oKEeLNUC9MVgvPThiTR?=	M4G2d\|IzOzN4MkS2
SNB78	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLLNE4xOS1zMECg{txO	NXXkOWdjPDhiaB?=		M4TPeGxw\yCJSUWwQU05NjZ3IF2=	MlTWNlI{OzZ{NE[=
HCC2998	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjFN3cxNjBzLUGwNEDPxE1?	NYLtVohuPDhiaB?=		Mmf6UI9oKEeLNUC9MVgvODViTR?=	M4XacFIzOzN4MkS2
KM12	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOwMlAyNTFyMDFOwG0>	NEPpOlg1QCCq		M1\3bWxw\yCJSUWwQU04NjV2IF2=	MlfaNlI{OzZ{NE[=
HT-29	NGrxeItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{L4WVAvODFvMUCwJO69VQ>?	MmG3OFghcA>?		M3u1WGxw\yCJSUWwQU04Njd3IF2=	MoHUNlI{OzZ{NE[=
HCT15	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHH5fVkxNjBzLUGwNEDPxE1?	NFfsWGw1QCCq		NWrJXGN2VG:pIFfJOVA:NThwMEOgUS=>	NIO5[ZMzOjN\|NkK0Oi=>
HCT116	NXfiW2FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLSNE4xOS1zMECg{txO	MorjOFghcA>?		NGjmWI9Nd2diR1m1NF0uPy54MTDN	MmLJNlI{OzZ{NE[=
NCI-H23	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33TPFAvODFvMUCwJO69VQ>?	M{LiZ\|Q5KGh?		NFj4TXFNd2diR1m1NF0uPy54NDDN	MnPNNlI{OzZ{NE[=
NCI-H226	MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEftR\|cxNjBzLUGwNEDPxE1?	MlzkOFghcA>?		NXj2VoE5VG:pIFfJOVA:NThwNESgUS=>	MVWyNlM{PjJ2Nh?=
NCI-H522	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPSNldoOC5yMT2xNFAh\|ryP	Ml\qOFghcA>?		M{HK[Wxw\yCJSUWwQU05NjR3IF2=	MmnZNlI{OzZ{NE[=
NCI-H438	M1vBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDtZocxNjBzLUGwNEDPxE1?	NVr5dlBRPDhiaB?=		NGfIRpVNd2diR1m1NF0uQC5zMTDN	Mn6wNlI{OzZ{NE[=
A549	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DLWlAvODFvMUCwJO69VQ>?	Ml\QOFghcA>?		MV7Mc4chT0l3ME2tPE4xPyCP	M2DQWlIzOzN4MkS2
DMS273	NWO5OHRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWKwMlAyNTFyMDFOwG0>	MmnPOFghcA>?		MkHQUI9oKEeLNUC9MVcvQDBiTR?=	NUX3W3hPOjJ\|M{[yOFY>
DMS114	NGnB[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVmwMlAyNTFyMDFOwG0>	NGXodZU1QCCq		MX7Mc4chT0l3ME2tPE4{QSCP	MYeyNlM{PjJ2Nh?=
LOXIMVI	MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWKwMlAyNTFyMDFOwG0>	NH;6VmY1QCCq		MoXtUI9oKEeLNUC9MVgvPjZiTR?=	MYiyNlM{PjJ2Nh?=
OVCAR3	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWiwMlAyNTFyMDFOwG0>	M{D0fVQ5KGh?		MUjMc4chT0l3ME2tPE4yPyCP	MXuyNlM{PjJ2Nh?=
OVCAR4	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrGNE4xOS1zMECg{txO	NYHmZmhkPDhiaB?=		NIni[29Nd2diR1m1NF0uQC53ODDN	NGjBUlYzOjN\|NkK0Oi=>
OVCAR5	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4f2dlAvODFvMUCwJO69VQ>?	MmTjOFghcA>?		NGLlSJhNd2diR1m1NF0uPy53NzDN	MoXVNlI{OzZ{NE[=
OVCAR8	NGTrXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPuTVlGOC5yMT2xNFAh\|ryP	MUK0PEBp		NUTmNZFjVG:pIFfJOVA:NTdwOESgUS=>	NFTMVJgzOjN\|NkK0Oi=>
SKOV3	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHoepNNOC5yMT2xNFAh\|ryP	M{\ubVQ5KGh?		MWrMc4chT0l3ME2tPE41OSCP	M{m2NVIzOzN4MkS2
RXF631L	NEXKUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;LO3QxNjBzLUGwNEDPxE1?	NFP4N2g1QCCq		MWHMc4chT0l3ME2tPE4zOSCP	NFTu[3gzOjN\|NkK0Oi=>
ACHN	M2L1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPFXG5EOC5yMT2xNFAh\|ryP	NG\FVmI1QCCq		M1\Oe2xw\yCJSUWwQU04Njl3IF2=	Mk\DNlI{OzZ{NE[=
St-4	NUfpNIRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYiwMlAyNTFyMDFOwG0>	NV76dmJvPDhiaB?=		NGm4UVNNd2diR1m1NF0uPy52NzDN	NVLVOnNzOjJ\|M{[yOFY>
MKN1	NHK1XZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHqNE4xOS1zMECg{txO	NH7UXGY1QCCq		M4LtZmxw\yCJSUWwQU05NjRzIF2=	M4rTO\|IzOzN4MkS2
MKN7	NH3CO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqwMlAyNTFyMDFOwG0>	MYS0PEBp		NIXqN\|NNd2diR1m1NF0uPy54ODDN	NHHUZnAzOjN\|NkK0Oi=>
MKN28	NVjFXHY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvmcFNNOC5yMT2xNFAh\|ryP	NUHh[HFUPDhiaB?=		NV3zT4x[VG:pIFfJOVA:NTdwMEegUS=>	NWjYeVhOOjJ\|M{[yOFY>
MKN45	Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{K2SVAvODFvMUCwJO69VQ>?	MVm0PEBp		MUDMc4chT0l3ME2tPE4{PCCP	NEH2UVkzOjN\|NkK0Oi=>
MKN74	NGPXdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofoNE4xOS1zMECg{txO	NXmyenloPDhiaB?=		NIrqd3BNd2diR1m1NF0uPy52MjDN	NWHxTIJ4OjJ\|M{[yOFY>
DU145	Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUOwMlAyNTFyMDFOwG0>	MUS0PEBp		NV;UepFVVG:pIFfJOVA:NThwMU[gUS=>	M3XnS\|IzOzN4MkS2
PC3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6wMlAyNTFyMDFOwG0>	MWi0PEBp		NFrwXZlNd2diR1m1NF0uQC54NjDN	MX6yNlM{PjJ2Nh?=
Trypanosoma brucei brucei	MVfGeY5kfGmxbjDBd5NigQ>?	NFe0Om4zODBibl2=	NHXJT2wyOiCq	MkHmSG1UVw>?	MkCxSIVkemWjc3WgbY4heGixc4Doc5Rq\HmuIHnuc5NqfG:uIIDoc5NxcGG2ZTDs[ZZmdA>?	NVKwc\|QxOjR6MEW5OFY>
Trypanosoma brucei brucei	Mk\lSpVv[3Srb36gRZN{[Xl?		MXixPEBp	NXjCUFdDTE2VTx?=	NVvJ[WFYUW6qaXLpeIlwdiCxZjDy[YNmeHSxcj3t[YRq[XSnZDDlcoRw[3m2b4Ppd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjD0doFve2[ncoLpckB2eHSja3W=	M2P0fFI1QDB3OUS2
Trypanosoma brucei brucei	M1z5b2Z2dmO2aX;uJGF{e2G7	NYLjeW5KOjByIH7N	MlHINVIhcA>?	NYTDOmZkTE2VTx?=	MljPSYZn\WO2IH;uJJNxcGmwZ3;tfYxmcW5ibHX2[Yw>	NIf0bFQzPDhyNUm0Oi=>
Trypanosoma brucei brucei	M1;wOmZ2dmO2aX;uJGF{e2G7	NYfuWmRjOjByIH7N	MYmxNkBp	M4T3c2ROW09?	MoDSSYZn\WO2IH;uJJBpd3OyaHH0bYR6dGOqb3zpcoUhdGW4ZXy=	MXiyOFgxPTl2Nh?=
UM-UC-3	NI[2R2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:y[ZlKSzVyPUOxOUBxVQ>?	MY\TRW5ITVJ?
SBC-1	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTd2MjDwUS=>	NWrtRYo2W0GQR1XS
MKN1	NG\TOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULVcJJMUUN3ME2yMlghdk1?	NHXXSplUSU6JRWK=
NCI-H720	M3TNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH6TJJxUUN3ME2zMlU4KG6P	NXnYWYFPW0GQR1XS
BFTC-909	NH3Ve\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVX5OVRtUUN3ME2zMlcyKG6P	M{\4V3NCVkeHUh?=
BPH-1	NITuXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\2fmd2UUN3ME20Mlc3KG6P	M1i3WXNCVkeHUh?=
PC-3	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{n6U2lEPTB;NT6wPUBvVQ>?	M1HwOHNCVkeHUh?=
AN3-CA	M3jFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjLXYlKSzVyPUWuOVYhdk1?	MVfTRW5ITVJ?
HN	NFPHS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPscolKSzVyPUWuPVYhdk1?	M2CzeHNCVkeHUh?=
HCC2218	M1:0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjUTWM2OD14Lk[xJI5O	NXPKNW5ZW0GQR1XS
KP-4	NYjudWFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnNO3RTUUN3ME23JI5O	MnLpV2FPT0WU
LU-139	M4fUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnqWXlGUUN3ME23Mlc4KG6P	M4PM[HNCVkeHUh?=
ETK-1	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTBdoFKSzVyPUeuPFghdk1?	MX\TRW5ITVJ?
Ramos-2G6-4C10	M1\uV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXThVpFHUUN3ME24MlQ6KG6P	MUfTRW5ITVJ?
MHH-PREB-1	MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWD2Ulc1UUN3ME25MlEzKG6P	Mkj6V2FPT0WU
DU-4475	NXTadmV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7PTWM2OD17LkS0JI5O	M2jjVnNCVkeHUh?=
NCI-H1666	NYfwfVlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfyN5NKUUN3ME25MlcyKG6P	M3HOTXNCVkeHUh?=
CAMA-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTlwODDuUS=>	M1jKcXNCVkeHUh?=
TYK-nu	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTlwOUSgcm0>	NGf1d2FUSU6JRWK=
MFE-280	NX7pNGZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nVemlEPTB;OT65PUBvVQ>?	NGXOV4VUSU6JRWK=
A549	M3TJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPQTppiUUN3ME2xNE4yPCCwTR?=	MoHjV2FPT0WU
769-P	NGXiPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTYSmJKSzVyPUGwMlQ1KG6P	NWrjNnhDW0GQR1XS
L-363	M3;1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PNRWlEPTB;MUCuOlkhdk1?	MVrTRW5ITVJ?
ES8	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGW1clJKSzVyPUGwMlkhdk1?	MmDpV2FPT0WU
PA-1	M4W2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFzLkiyJI5O	NGrremhUSU6JRWK=
Mewo	M3jMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTFzLkm5JI5O	NYfxe2V5W0GQR1XS
HSC-3	NVr0PVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPoTWM2OD1zMj6yNUBvVQ>?	NIjOcXdUSU6JRWK=
H4	NEPvS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULZVYZLUUN3ME2xNk43PyCwTR?=	NVfkT4NUW0GQR1XS
BB65-RCC	NYjPV4UzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTF{LkeyJI5O	MUnTRW5ITVJ?
NCI-H1793	NVO3ZnVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DNVWlEPTB;MUKuPFIhdk1?	Mly4V2FPT0WU
KARPAS-45	NWLr[FdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLpTWM2OD1zMz61NUBvVQ>?	M1fHOXNCVkeHUh?=
GCT	NEXHPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEThUWxKSzVyPUGzMlY5KG6P	MYnTRW5ITVJ?
EoL-1	NFTC[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LVUmlEPTB;MUOuPVMhdk1?	NXntfo9UW0GQR1XS
LB2241-RCC	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTF2LkCxJI5O	Mn7LV2FPT0WU
ES5	NH;WO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;kW2lEPTB;MUSuO\|Qhdk1?	M3fVcnNCVkeHUh?=
LOXIMVI	NWPQS2RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVyzWlZbUUN3ME2xOE46QSCwTR?=	MXrTRW5ITVJ?
COR-L105	M3vvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGmzXYFKSzVyPUG1MlA1KG6P	NWD0UYFCW0GQR1XS
P12-ICHIKAWA	NUHydFdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWn0UGZQUUN3ME2xOU4yKG6P	MWnTRW5ITVJ?
CHL-1	NUTyeIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO3TWM2OD1zNT60OUBvVQ>?	M{fEUnNCVkeHUh?=
VMRC-RCZ	NYjRWYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTrbplKSzVyPUG1MlY{KG6P	NHvhNFBUSU6JRWK=
HH	M3fWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXz6V21{UUN3ME2xOU44KG6P	M3voenNCVkeHUh?=
NUGC-3	MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTF4LkO0JI5O	M1joSnNCVkeHUh?=
EGI-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTlTWM2OD1zNj60N{BvVQ>?	MXnTRW5ITVJ?
OS-RC-2	NX;Y[5ljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLpTWM2OD1zNj60O{BvVQ>?	MWjTRW5ITVJ?
MOLT-16	MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVi2[lVbUUN3ME2xO{4yPSCwTR?=	MljjV2FPT0WU
NCI-H209	MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTF5LkK5JI5O	M4ixcnNCVkeHUh?=
697	MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\CTWM2OD1zNz60N{BvVQ>?	NFvreZZUSU6JRWK=
D-56MG	NFjXfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrkTWM2OD1zNz62PUBvVQ>?	MmXCV2FPT0WU
VA-ES-BJ	MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXu1S\|ZjUUN3ME2xO{45OyCwTR?=	Mor6V2FPT0WU
EW-16	NV;EVGduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljZTWM2OD1zOD6wOEBvVQ>?	NV7DTJV{W0GQR1XS
HGC-27	Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzZZVVKSzVyPUG4MlA3KG6P	NVLEcmtLW0GQR1XS
ES7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTF6LkC5JI5O	M3;jTHNCVkeHUh?=
HuH-7	M3Ho[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTF6LkSgcm0>	MWrTRW5ITVJ?
BCPAP	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTF6Lk[1JI5O	MoP6V2FPT0WU
SW1710	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfQTWM2OD1zOD63NkBvVQ>?	NGDvWWhUSU6JRWK=
IST-MEL1	NF;LTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTF6Lke3JI5O	MULTRW5ITVJ?
SF295	NEfBdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PTUWlEPTB;MUiuPVMhdk1?	M13rV3NCVkeHUh?=
RPMI-7951	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\UTWlEPTB;MUmuNlghdk1?	M{LZTnNCVkeHUh?=
SF126	NUX5W\|BwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXadXFKSzVyPUG5MlQyKG6P	M{m5WnNCVkeHUh?=
GAMG	NI\pWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUK0RlVOUUN3ME2xPU41QCCwTR?=	MVfTRW5ITVJ?
KNS-81-FD	NUnvcoRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTF7LkW0JI5O	MXrTRW5ITVJ?
RT-112	NWizRoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXuSGV5UUN3ME2xPU43PiCwTR?=	MoTGV2FPT0WU
DEL	M2rzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPHfpBFUUN3ME2yNE41QSCwTR?=	M{TVUXNCVkeHUh?=
CGTH-W-1	NF3Ye4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfEWppTUUN3ME2yNE43OyCwTR?=	NF\vUIhUSU6JRWK=
HOS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJzLkC2JI5O	M1fnVHNCVkeHUh?=
ES4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLvTWM2OD1{MT6wPEBvVQ>?	MYnTRW5ITVJ?
RXF393	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTJzLkS1JI5O	MWfTRW5ITVJ?
NCI-H2030	NVnIbY9KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jhZWlEPTB;MkGuOVIhdk1?	NULtO4dqW0GQR1XS
YH-13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTJzLki4JI5O	NX;IfoM5W0GQR1XS
HT-1080	NHG0cW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HF[2lEPTB;MkGuPVMhdk1?	M3PKV3NCVkeHUh?=
NCI-SNU-1	NGjUNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnabGhTUUN3ME2yNU46PSCwTR?=	M{W1UHNCVkeHUh?=
G-402	MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7RTWM2OD1{Mj6xOkBvVQ>?	MVTTRW5ITVJ?
786-0	NWrPe4ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJ{LkK5JI5O	MYrTRW5ITVJ?
ME-180	NH\WfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUOzPFdmUUN3ME2yNk41OyCwTR?=	NH\yd2tUSU6JRWK=
NB69	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDW[XZNUUN3ME2yNk42OyCwTR?=	MYfTRW5ITVJ?
J-RT3-T3-5	M162RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TEbmlEPTB;MkKuPVYhdk1?	NIjoW4lUSU6JRWK=
TGBC1TKB	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnycW1KSzVyPUKzMlA2KG6P	NXLRb2JCW0GQR1XS
SW780	M2HiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHHTWM2OD1{Mz6xN{BvVQ>?	MYXTRW5ITVJ?
MG-63	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;jTWM2OD1{Mz60OUBvVQ>?	NYLqS5duW0GQR1XS
BV-173	NHTSSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzYcHhKSzVyPUKzMlg4KG6P	MUHTRW5ITVJ?
CAL-51	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TPd2lEPTB;MkOuPFkhdk1?	M1;zenNCVkeHUh?=
A375	NV2xUlVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPEdXdyUUN3ME2yN{46OyCwTR?=	MYrTRW5ITVJ?
MEL-HO	NV\sXnMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJ2LkC0JI5O	M17vWnNCVkeHUh?=
EFO-27	NHn6fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf0RpZMUUN3ME2yOE4{OyCwTR?=	NX[1emFoW0GQR1XS
Hs-578-T	NIiwfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYC0S4x4UUN3ME2yOE42QCCwTR?=	MmP4V2FPT0WU
NBsusSR	M2XJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHmOW9KSzVyPUK0MlYhdk1?	MlW2V2FPT0WU
CTB-1	M1PqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJ2Lk[3JI5O	NIK4[4dUSU6JRWK=
FTC-133	NGTS[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHsTWM2OD1{NT6xJI5O	M3jKUXNCVkeHUh?=
MOLT-4	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PPbWlEPTB;MkWuNVIhdk1?	NF3xUYxUSU6JRWK=
HO-1-N-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PTeGlEPTB;MkWuNVUhdk1?	NV[0UIZwW0GQR1XS
ES3	NVfqR4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnpclRnUUN3ME2yOU4zOiCwTR?=	MofLV2FPT0WU
TI-73	NEjWU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\OVZZKSzVyPUK1MlI5KG6P	M2jGcnNCVkeHUh?=
MPP-89	NVHVTIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTiTWM2OD1{NT6zNkBvVQ>?	NYLnRW57W0GQR1XS
KYSE-150	NXH1NndIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO3TWM2OD1{NT64PUBvVQ>?	M4PZNnNCVkeHUh?=
LXF-289	NIPBXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTJ4LkC0JI5O	MkHsV2FPT0WU
SK-LU-1	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrlfZVKSzVyPUK2MlE4KG6P	M3ztenNCVkeHUh?=
HOP-92	NEHLcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGThVI1KSzVyPUK2MlQ5KG6P	NV;LUXg6W0GQR1XS
HuO9	NX\wU3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTJ4Lke2JI5O	NXLwZWo2W0GQR1XS
SW962	NXrnOFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJ4Lke2JI5O	MUjTRW5ITVJ?
RS4-11	NXTsUJFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PTeGlEPTB;Mk[uPVEhdk1?	M{nYSHNCVkeHUh?=
NCI-H292	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH32e\|VKSzVyPUK3JI5O	NXTidmdFW0GQR1XS
DB	NV;0fWdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDSRnFKSzVyPUK3MlM3KG6P	M3zVO3NCVkeHUh?=
SW1088	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;OdHVKSzVyPUK4MlI6KG6P	MXvTRW5ITVJ?
A204	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7SU3J[UUN3ME2yPE41PyCwTR?=	MVnTRW5ITVJ?
A3-KAW	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TrS2lEPTB;MkiuOlQhdk1?	M{jJ[3NCVkeHUh?=
MV-4-11	M3;USWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHSTIk6UUN3ME2yPE44KG6P	M{LmdHNCVkeHUh?=
ES1	NWfkRm5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTJ6Lki0JI5O	MVPTRW5ITVJ?
ONS-76	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJ7LkC1JI5O	NEi4SW1USU6JRWK=
D-263MG	NXj0emR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLyfVBTUUN3ME2yPU4{PSCwTR?=	MYrTRW5ITVJ?
U-2-OS	NUTvWoZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF62VGJKSzVyPUK5MlUhdk1?	M3q5OnNCVkeHUh?=
T98G	MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zYTmlEPTB;MkmuPFghdk1?	Mn;pV2FPT0WU
GI-ME-N	M4XiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfqSXJKSzVyPUK5MlkyKG6P	MlzFV2FPT0WU
BHT-101	M2TBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnk[FhWUUN3ME2zNE4xPSCwTR?=	NXe5eGpMW0GQR1XS
NOS-1	NFL1NHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXhTWM2OD1\|MD6xNkBvVQ>?	MmWyV2FPT0WU
AsPC-1	NFr1PFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPVOndKSzVyPUOwMlIhdk1?	MnfPV2FPT0WU
QIMR-WIL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3GzWWlEPTB;M{CuOkBvVQ>?	M{myO3NCVkeHUh?=
JVM-3	NYi2XZA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzUTWM2OD1\|MD64N{BvVQ>?	MkTtV2FPT0WU
KU-19-19	M{D2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mom2TWM2OD1\|MT6xN{BvVQ>?	M3HnOXNCVkeHUh?=
OVCAR-8	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTNzLkK2JI5O	NVHPbZhrW0GQR1XS
BEN	NWjkZXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4ToWWlEPTB;M{GuOlMhdk1?	MmraV2FPT0WU
BE-13	NEjQcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXjN3lKSzVyPUOxMlgzKG6P	NUTWTHpVW0GQR1XS
EW-18	MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvMeXpKSzVyPUOxMlg3KG6P	MYrTRW5ITVJ?
ECC10	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjXb\|V3UUN3ME2zNU46PSCwTR?=	NHPqRWhUSU6JRWK=
CTV-1	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fIUmlEPTB;M{KuPFIhdk1?	M1racXNCVkeHUh?=
COLO-800	NIqxNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvybVdKSzVyPUOyMlkzKG6P	MVHTRW5ITVJ?
A2058	M3THeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3ke5hKSzVyPUOzMlI2KG6P	MXLTRW5ITVJ?
VM-CUB-1	NHjZSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTN\|LkSzJI5O	NHiwVGdUSU6JRWK=
Ca9-22	M2LZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfmVXl{UUN3ME2zN{42PSCwTR?=	MUnTRW5ITVJ?
COLO-684	M4TZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7YTWM2OD1\|Mz61PEBvVQ>?	Mn;aV2FPT0WU
RPMI-8226	NVjYfoxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLyVpdKSzVyPUOzMlgzKG6P	M1y2THNCVkeHUh?=
SK-NEP-1	M{LhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HHfGlEPTB;M{SuNVUhdk1?	NIrT[VNUSU6JRWK=
Becker	NXr1PY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnryTWM2OD1\|ND6yNUBvVQ>?	NVS5b3RSW0GQR1XS
NCI-H28	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTN2LkS0JI5O	NXTEVpA1W0GQR1XS
CAL-120	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTN2LkeyJI5O	M124XnNCVkeHUh?=
MDA-MB-157	NYDWOnE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nQ[WlEPTB;M{WuOFEhdk1?	NYL5TWpxW0GQR1XS
OVCAR-5	M1e0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXO5XZR5UUN3ME2zOU41PyCwTR?=	NFnNPYhUSU6JRWK=
LAMA-84	NYGxd\|hmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2j0XGlEPTB;M{WuPFchdk1?	MXzTRW5ITVJ?
CAKI-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDPfXBKSzVyPUO2MlQ{KG6P	MYXTRW5ITVJ?
Daoy	M4fQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVn5cHo3UUN3ME2zOk44KG6P	NE\LSpBUSU6JRWK=
CAL-62	Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTN4Lki2JI5O	NEe5fHJUSU6JRWK=
8-MG-BA	NIrLXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\2d2lEPTB;M{euNlUhdk1?	MkDjV2FPT0WU
8505C	M1TrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDLXll[UUN3ME2zO{42OSCwTR?=	NGnDVYlUSU6JRWK=
LNCaP-Clone-FGC	NYW2VXlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfNemNpUUN3ME2zO{42QSCwTR?=	NFH5fZNUSU6JRWK=
CAL-39	NG\iOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnXS5Y2UUN3ME2zO{46KG6P	NFjFTG5USU6JRWK=
MN-60	NWmwUnlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1e3RmlEPTB;M{euPVYhdk1?	NY\BNG9XW0GQR1XS
RKO	M1PpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDsdWVFUUN3ME2zPE4{OyCwTR?=	MnK4V2FPT0WU
U251	NWLmbHprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTN6LkSzJI5O	MlXSV2FPT0WU
SJSA-1	M2jjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVO5SmZrUUN3ME2zPE42PCCwTR?=	Mom3V2FPT0WU
CAL-12T	NFrsdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7NUGxlUUN3ME2zPE43KG6P	MnPjV2FPT0WU
HCC1419	M3L6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4X5Z2lEPTB;M{iuO\|Ehdk1?	NFTwS4pUSU6JRWK=
CO-314	NXKwUIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXX6OmNsUUN3ME2zPE44PCCwTR?=	MlXNV2FPT0WU
LB1047-RCC	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTN6LkixJI5O	MVjTRW5ITVJ?
A101D	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTN6Lkm3JI5O	MlHIV2FPT0WU
MDA-MB-175-VII	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\STWM2OD1\|OT61NUBvVQ>?	MXfTRW5ITVJ?
MZ2-MEL	M{TPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLUOGhKSzVyPUO5MlY3KG6P	NETS[lVUSU6JRWK=
NB5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjSZ5VZUUN3ME20NE43PCCwTR?=	MlvKV2FPT0WU
G-401	NFzPdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTRyLkiyJI5O	NVrXTnQ1W0GQR1XS
HT	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fDTmlEPTB;NEGuNFIhdk1?	Mo\vV2FPT0WU
8305C	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFj4OINKSzVyPUSxMlg4KG6P	MWDTRW5ITVJ?
BHY	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTR{LkeyJI5O	MXvTRW5ITVJ?
NTERA-S-cl-D1	NXzTN2g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoK1TWM2OD12MzDuUS=>	MY\TRW5ITVJ?
T-24	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTR\|LkizJI5O	NV;reY5KW0GQR1XS
EPLC-272H	NX;5O\|l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrjTWM2OD12ND6zPUBvVQ>?	NFe2eo5USU6JRWK=
PSN1	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTR2LkSgcm0>	NWPnboJCW0GQR1XS
NCI-H2452	MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGH1N\|hKSzVyPUS0MlU5KG6P	NX2zeWZYW0GQR1XS
KS-1	NIfj[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\xTWM2OD12ND62OkBvVQ>?	NWDtb4NDW0GQR1XS
HD-MY-Z	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\sUo1KSzVyPUS0MlkzKG6P	MnzmV2FPT0WU
KNS-62	NHy4R\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2P5XmlEPTB;NEWuN\|ghdk1?	Mk\FV2FPT0WU
NOMO-1	NFGwXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;PXJFKSzVyPUS1Mlg4KG6P	Mmm3V2FPT0WU
SK-HEP-1	NGrXOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHH0UW5KSzVyPUS2MlA1KG6P	MULTRW5ITVJ?
IGR-1	M2\pUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLLRZFkUUN3ME20Ok4yOyCwTR?=	MVPTRW5ITVJ?
KYSE-180	NV\ydZVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVmyVW5TUUN3ME20Ok4yPyCwTR?=	NIPQVY1USU6JRWK=
EW-22	NX7o[4p5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrCWFc6UUN3ME20Ok4zKG6P	NV70U4Y3W0GQR1XS
NCI-H1355	M33SZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETre2RKSzVyPUS2MlM1KG6P	M4TPdnNCVkeHUh?=
DOHH-2	NEDiPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LhPGlEPTB;NE[uN\|chdk1?	MknyV2FPT0WU
A4-Fuk	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfoTWM2OD12Nj61NkBvVQ>?	M4rncXNCVkeHUh?=
PC-14	NX3UfHVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LsbWlEPTB;NE[uOVchdk1?	NXn2O\|B5W0GQR1XS
TE-5	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTR4Lki0JI5O	M2\XdnNCVkeHUh?=
LB996-RCC	M3TtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDETWM2OD12Nz6xPUBvVQ>?	Ml;BV2FPT0WU
NCI-H1623	M3z5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDaPVBKSzVyPUS3Mlc3KG6P	MXXTRW5ITVJ?
NCI-H1155	M1flUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTR6LkOyJI5O	NVfoenlQW0GQR1XS
LoVo	M3j5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnuZ2RKSzVyPUS4MlQhdk1?	M3THR3NCVkeHUh?=
MCF7	M1jrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fSXWlEPTB;NEiuOVghdk1?	M4O5R3NCVkeHUh?=
AGS	NWTG[m5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTxV4VKSzVyPUS4Mlc4KG6P	MW\TRW5ITVJ?
PFSK-1	NYLOZ4pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjZdGpIUUN3ME20PU4xPiCwTR?=	MYDTRW5ITVJ?
22RV1	NWfCZ2d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fGW2lEPTB;NEmuNFkhdk1?	M2jTVHNCVkeHUh?=
COR-L23	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2G4U2lEPTB;NEmuNVYhdk1?	NWXRXHhFW0GQR1XS
D-283MED	MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnU[GpqUUN3ME20PU43OSCwTR?=	NEPlXYJUSU6JRWK=
SW982	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXUWItLUUN3ME20PU46OSCwTR?=	M4[zc3NCVkeHUh?=
SW620	NEXUelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzDNXNKSzVyPUWwMlM3KG6P	M2fmPHNCVkeHUh?=
KYSE-140	M3vv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3SyeWlEPTB;NUCuOVUhdk1?	MmDLV2FPT0WU
GCIY	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrsd\|F3UUN3ME21NE43PyCwTR?=	M{fTfXNCVkeHUh?=
MHH-ESS-1	NEH2fXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIW2NWZKSzVyPUWxMlk2KG6P	NGnp[W9USU6JRWK=
D-423MG	MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTV{LkC4JI5O	MW\TRW5ITVJ?
SF539	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTV{LkO1JI5O	MYLTRW5ITVJ?
RPMI-2650	NXnwTY51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHyTWM2OD13Mj62PUBvVQ>?	MULTRW5ITVJ?
GR-ST	MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTV{Lki3JI5O	M2SxUHNCVkeHUh?=
YKG-1	NW\1eGtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLa[pNOUUN3ME21N{BvVQ>?	NIG0WmlUSU6JRWK=
SK-MES-1	NYXuUo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmO5TWM2OD13Mz6yOkBvVQ>?	MnTIV2FPT0WU
HLE	NGfkZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1OzZ2lEPTB;NUOuOFchdk1?	NUHkfVlUW0GQR1XS
RVH-421	M1XkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HmPGlEPTB;NUOuOlchdk1?	MorIV2FPT0WU
C32	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7pfotKSzVyPUWzMlg{KG6P	Mlz6V2FPT0WU
GB-1	NVzlXXo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTV2LkKgcm0>	MWTTRW5ITVJ?
SNB75	NX61cItzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTV2LkK2JI5O	MUTTRW5ITVJ?
EM-2	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DUSmlEPTB;NUSuOEBvVQ>?	NVznbXZrW0GQR1XS
RH-1	NWrCNnoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\STWM2OD13ND63JI5O	MnH1V2FPT0WU
NKM-1	NVLu[I9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrMcIZJUUN3ME21OE45OSCwTR?=	NEfHXFJUSU6JRWK=
NCI-H2405	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTV2Lki4JI5O	NUTBRlg1W0GQR1XS
KYSE-450	NF\oV\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjnRWMyUUN3ME21OU4yPiCwTR?=	M4riOXNCVkeHUh?=
A704	MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTV3LkW5JI5O	M4fTfnNCVkeHUh?=
HAL-01	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjiO4VKSzVyPUW1Mlg{KG6P	NFn3cHdUSU6JRWK=
TE-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mme0TWM2OD13NT65PUBvVQ>?	MVrTRW5ITVJ?
DOK	M{S2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnpfVJzUUN3ME21Ok4xOiCwTR?=	MVTTRW5ITVJ?
KY821	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzuWXVKSzVyPUW2MlIhdk1?	MoriV2FPT0WU
KGN	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnScJRKSzVyPUW2MlMzKG6P	NVTKSZlUW0GQR1XS
MC116	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1OyT2lEPTB;NUeuPEBvVQ>?	NIPrRZRUSU6JRWK=
PANC-08-13	NWrHN\|VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPWTWM2OD13OD6wNUBvVQ>?	NIPXeHRUSU6JRWK=
KE-37	NWfmb3FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrsNpd5UUN3ME21PE44PyCwTR?=	NFviWI5USU6JRWK=
KYSE-410	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\hSYVKSzVyPUW5MlQ4KG6P	NUDHOpdjW0GQR1XS
RO82-W-1	NIHWOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTV7Lkmgcm0>	NHr6fldUSU6JRWK=
M14	NW\JT5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLkTWM2OD14MD6wOEBvVQ>?	M2TtcXNCVkeHUh?=
GI-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnKWJNtUUN3ME22NE4{KG6P	NWrHW4kxW0GQR1XS
ML-2	M4rN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLrdZNbUUN3ME22NE43OiCwTR?=	NHrNcWlUSU6JRWK=
BFTC-905	NGnMRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PLVmlEPTB;NkCuOlUhdk1?	M1\jRXNCVkeHUh?=
DMS-273	M1rmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPGTWM2OD14MD64O{BvVQ>?	NIfjb3VUSU6JRWK=
MDA-MB-361	NVLwb\|BOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF65VopKSzVyPU[xJI5O	M4rTdHNCVkeHUh?=
MSTO-211H	M{HSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnnfHpKSzVyPU[zMlUyKG6P	MoG5V2FPT0WU
MEG-01	NX\TO2piT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\KV2lEPTB;NkOuOVIhdk1?	NEP1SHpUSU6JRWK=
M059J	M4rPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXGcWxuUUN3ME22N{42QCCwTR?=	MkTsV2FPT0WU
LN-405	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvETWM2OD14Mz64OUBvVQ>?	NYnZTmwzW0GQR1XS
NCI-H1581	NITjU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmf0TWM2OD14ND6wN{BvVQ>?	MlHvV2FPT0WU
TCCSUP	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\mTWlEPTB;NkSuOVMhdk1?	NFvDZ\|dUSU6JRWK=
SW872	NXrldXM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWL5Zlh[UUN3ME22OE42PyCwTR?=	MWXTRW5ITVJ?
KYSE-510	M2flNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfTTWM2OD14NT63OUBvVQ>?	NWnkNpFxW0GQR1XS
NCI-H1792	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTZ4LkG1JI5O	MmrQV2FPT0WU
SW13	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnOTWM2OD14Nj61JI5O	M33DN3NCVkeHUh?=
TE-8	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzyTWM2OD14Nj61NkBvVQ>?	NI\3[lFUSU6JRWK=
SCH	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYCyfZFtUUN3ME22O{4yKG6P	M4j1VXNCVkeHUh?=
NEC8	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTZ5LkK0JI5O	MYjTRW5ITVJ?
HuO-3N1	NX3hdos3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XHdWlEPTB;NkeuN\|Ehdk1?	MWrTRW5ITVJ?
EFM-19	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\5TWM2OD14Nz61JI5O	MoO3V2FPT0WU
HEC-1	NWH1RZFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonKTWM2OD14Nz61NkBvVQ>?	NVnnbJZzW0GQR1XS
T47D	NXW1NpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\vcJk1UUN3ME22O{45PyCwTR?=	NUezbJd6W0GQR1XS
SNU-423	NEG1bXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfXfWR4UUN3ME22O{46QCCwTR?=	M2rqdnNCVkeHUh?=
WM-115	Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXixbVRRUUN3ME22PE4yPCCwTR?=	NV:0c\|JpW0GQR1XS
CaR-1	NWnlUplnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXpZ3NKSzVyPU[4MlI2KG6P	MnTMV2FPT0WU
KU812	M{PXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHvWVhWUUN3ME22PE43QSCwTR?=	MWPTRW5ITVJ?
AM-38	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3uTWM2OD14OT6zNUBvVQ>?	NXLkNXhjW0GQR1XS
KOSC-2	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTZ7Lkm3JI5O	NXzNfGFKW0GQR1XS
MC-IXC	M{jHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonUTWM2OD15MD6wPEBvVQ>?	NHjzd2lUSU6JRWK=
SCC-4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHpTWM2OD15MT6zPEBvVQ>?	M{TZbHNCVkeHUh?=
Calu-3	NFf6THJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrRZmhKSzVyPUexMlk5KG6P	MnLaV2FPT0WU
RPMI-8866	M{PsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGntXlNKSzVyPUeyMlgzKG6P	MXfTRW5ITVJ?
OVCAR-4	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGOzc5RKSzVyPUezMlM3KG6P	Ml;HV2FPT0WU
OAW-42	M1ez[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\OfpJVUUN3ME23N{4{QSCwTR?=	NV;DTHQ5W0GQR1XS
ATN-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vPcGlEPTB;N{OuPFchdk1?	MoXIV2FPT0WU
CHP-212	NYXHeWNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETkemxKSzVyPUe0Mlk2KG6P	MUPTRW5ITVJ?
C2BBe1	NW\SXpA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTd3LkCzJI5O	MUHTRW5ITVJ?
A498	NXTTNms1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTd3LkG1JI5O	NUHNN2Y{W0GQR1XS
SH-4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HTemlEPTB;N{WuNlEhdk1?	MmC1V2FPT0WU
SNU-449	M4HPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXCTWM2OD15NT63PUBvVQ>?	Mk\hV2FPT0WU
RD	M2r5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;CTWM2OD15NT64OkBvVQ>?	NXnoe5BTW0GQR1XS
PANC-03-27	MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHuTWM2OD15Nj6yOUBvVQ>?	M1XmNXNCVkeHUh?=
S-117	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHMTWM2OD15Nj6yO{BvVQ>?	NWjQVZpSW0GQR1XS
SK-MEL-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4CyUWlEPTB;N{[uO\|Uhdk1?	NFXHSnhUSU6JRWK=
LK-2	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXFbY5TUUN3ME23O{4xPSCwTR?=	MUTTRW5ITVJ?
CP50-MEL-B	M2P6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{C3VWlEPTB;N{euOEBvVQ>?	M2XJZXNCVkeHUh?=
647-V	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;SfmlEPTB;N{iuNFchdk1?	MWjTRW5ITVJ?
LU-134-A	NYXPS4lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfNbHB{UUN3ME23PU4xOyCwTR?=	NHznTo5USU6JRWK=
5637	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPDTWM2OD15OT6yN{BvVQ>?	Ml:2V2FPT0WU
NCI-H1437	NVTTPJNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHOWYpKSzVyPUiwMlUhdk1?	MXvTRW5ITVJ?
NCI-H460	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;3TWM2OD16MT6yN{BvVQ>?	NYHzV49QW0GQR1XS
BxPC-3	NFXZTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{n5eWlEPTB;OEGuOFYhdk1?	MWLTRW5ITVJ?
CAN	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRThzLki0JI5O	MmfsV2FPT0WU
KINGS-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zwcWlEPTB;OEKuN\|Ihdk1?	NGLMbmlUSU6JRWK=
OCUB-M	M4jOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4H4[WlEPTB;OEKuOFEhdk1?	NUnKXXpPW0GQR1XS
KALS-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTh{LkW0JI5O	NGTJVXlUSU6JRWK=
OCI-AML2	M{XjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrTeldRUUN3ME24Nk43OSCwTR?=	M3jQOXNCVkeHUh?=
A253	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{C4N2lEPTB;OEKuOlUhdk1?	MVvTRW5ITVJ?
LCLC-97TM1	NGD2XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fodmlEPTB;OEKuPFYhdk1?	MoXUV2FPT0WU
NCI-H520	NH\tcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTh\|LkC2JI5O	MUXTRW5ITVJ?
P30-OHK	NWXt[3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTh\|LkWgcm0>	Mo\yV2FPT0WU
SBC-5	MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLLTWM2OD16Mz61NkBvVQ>?	MUjTRW5ITVJ?
HCE-T	NXfDZ4JyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkiyTWM2OD16Mz63OEBvVQ>?	NF;uOoxUSU6JRWK=
JEG-3	NVPLR3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DwfWlEPTB;OESuNUBvVQ>?	MXnTRW5ITVJ?
KG-1	NVTmd41JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3i[JdnUUN3ME24OE4zPCCwTR?=	M2PIeXNCVkeHUh?=
MIA-PaCa-2	NY\IZoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfNcnNKSzVyPUi0MlU1KG6P	NHS5[nBUSU6JRWK=
CAL-33	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPWTWM2OD16NT6wPEBvVQ>?	MmKwV2FPT0WU
639-V	NVHUcmVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XZVmlEPTB;OEWuOFIhdk1?	NGHIN5lUSU6JRWK=
NCI-H1048	MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTh4LkOxJI5O	MWLTRW5ITVJ?
NCI-H1573	NWe2UGxwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LqWGlEPTB;OEeuOFghdk1?	NVPtSIR4W0GQR1XS
NCI-H2228	MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTh6LkK2JI5O	M333WnNCVkeHUh?=
NB14	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnYNm5uUUN3ME24PE4{KG6P	NInGUXJUSU6JRWK=
SCC-25	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LEWGlEPTB;OEmuPFIhdk1?	NWX1eo1kW0GQR1XS
A431	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLxOVJwUUN3ME24PU46PyCwTR?=	M4OxRnNCVkeHUh?=
SN12C	NFi0cVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfI[5BGUUN3ME25NE43OiCwTR?=	NVS0NGxGW0GQR1XS
HuCCT1	NEPjTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTlyLke2JI5O	MnHaV2FPT0WU
LS-123	NVXXRYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mke3TWM2OD17Mj6xPEBvVQ>?	MYDTRW5ITVJ?
CAL-85-1	M2DDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTl{LkS4JI5O	Mkn6V2FPT0WU
ES6	M3nqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\aTXhHUUN3ME25Nk45OyCwTR?=	MV7TRW5ITVJ?
NCI-H650	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7JTWM2OD17ND6wPUBvVQ>?	MXrTRW5ITVJ?
NCI-H446	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1j5RmlEPTB;OUWuNVIhdk1?	MmTvV2FPT0WU
EW-13	MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF:2NGFKSzVyPUm1Mlc2KG6P	NVznPWoxW0GQR1XS
HSC-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHsfYZKSzVyPUm1Mlg6KG6P	NF;jeXZUSU6JRWK=
U031	NIHicJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moe3TWM2OD17Nj63N{BvVQ>?	NVvSOFhnW0GQR1XS
EW-11	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTUTWM2OD17Nj64PEBvVQ>?	NXvMUnRYW0GQR1XS
GAK	NFTXc\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HSNmlEPTB;OUiuPVMhdk1?	MV7TRW5ITVJ?
SK-OV-3	M17mS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnxT5BKSzVyPUGwNE4xPyCwTR?=	NX;p[Vh6W0GQR1XS
OMC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfUTWM2OD1zMECuNVghdk1?	M2iwWXNCVkeHUh?=
TK10	NVLabXhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjBTWM2OD1zMECuNlEhdk1?	M4qzTnNCVkeHUh?=
EKVX	M3fsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvOVXoxUUN3ME2xNFAvPiCwTR?=	MkK5V2FPT0WU
Detroit562	MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnqVmJ2UUN3ME2xNFIvOTdibl2=	NV3W[JhLW0GQR1XS
SF268	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nHZmlEPTB;MUCyMlM1KG6P	NFW5ZnlUSU6JRWK=
SNU-387	NHq1eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TnemlEPTB;MUC0MlE4KG6P	NIm1XI5USU6JRWK=
MDA-MB-231	NF\RO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlKzTWM2OD1zMEWuNFYhdk1?	NEnqb4NUSU6JRWK=
NCI-H1563	NEfDbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rrO2lEPTB;MUC1MlE5KG6P	NUnqPGt3W0GQR1XS
D-502MG	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjhWnZxUUN3ME2xNFUvPyCwTR?=	NVHoSW5vW0GQR1XS
A2780	NWXoWW1GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTFyNj60O{BvVQ>?	NWn5d3lJW0GQR1XS
IA-LM	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnz3TWM2OD1zMEeuOVEhdk1?	M{HCWXNCVkeHUh?=
D-392MG	MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3izZWlEPTB;MUC3MlU1KG6P	M3\lRnNCVkeHUh?=
MS-1	MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLRT5NyUUN3ME2xNFcvPzFibl2=	NUHr[JBpW0GQR1XS
SW1990	NXe2PWJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPOe3NKSzVyPUGwPE42PCCwTR?=	MYrTRW5ITVJ?
HEL	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjC[lFnUUN3ME2xNFkvOjlibl2=	MkPjV2FPT0WU
SW1573	NWXmR457T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nrWmlEPTB;MUC5MlMyKG6P	M1TRdHNCVkeHUh?=
SW1783	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mln2TWM2OD1zMUCuNlIhdk1?	MoTKV2FPT0WU
COLO-680N	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTFzMD63OkBvVQ>?	MlnVV2FPT0WU
NCI-N87	NG\4VGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;0XVRKSzVyPUGxNU4xPCCwTR?=	NXXERY1tW0GQR1XS
SK-MEL-28	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjlOHpLUUN3ME2xNVEvPTVibl2=	Mnn1V2FPT0WU
BT-20	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFzMj6wNUBvVQ>?	NWmxVG1KW0GQR1XS
NCI-H1648	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHZUXBKSzVyPUGxN{BvVQ>?	MYTTRW5ITVJ?
no-11	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTFzMz6yPEBvVQ>?	NWTrWZB2W0GQR1XS
MOLT-13	NHP5d4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEexWZNKSzVyPUGxN{41PCCwTR?=	Ml\3V2FPT0WU
NCI-H2170	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\lTWM2OD1zMUSuOVEhdk1?	MVzTRW5ITVJ?
HTC-C3	NEDh[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPnOlJKSzVyPUGxOk45PSCwTR?=	MUPTRW5ITVJ?
LU-99A	NUL2VINGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3[1TWlEPTB;MUG3MlIyKG6P	M3:1eXNCVkeHUh?=
HCC2998	NH7yeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml25TWM2OD1zMUeuPVIhdk1?	MWDTRW5ITVJ?
NB13	M1H5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTFzNz65PUBvVQ>?	NUnUZWl4W0GQR1XS
GT3TKB	NHjDS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{SweGlEPTB;MUG4MlA5KG6P	M2HYNnNCVkeHUh?=
BT-549	NV:5[VFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\w[oFKSzVyPUGxPE46PSCwTR?=	NYPl[FNPW0GQR1XS
NCI-H747	M4m4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TNS2lEPTB;MUG5MlM1KG6P	NWThXodZW0GQR1XS
EW-1	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTF{MD6yJI5O	M1js[nNCVkeHUh?=
LB831-BLC	M4jISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17tXmlEPTB;MUKwMlY{KG6P	NYTPPFU6W0GQR1XS
NMC-G1	M1TZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF{MT6xNUBvVQ>?	MnW5V2FPT0WU
COLO-679	M{f4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nQ[mlEPTB;MUKyMlE2KG6P	NUXEdlhxW0GQR1XS
HL-60	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;memlEPTB;MUKzMlEhdk1?	NYLBPI5zW0GQR1XS
MKN7	NF3FO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\6TWM2OD1zMkOuPFMhdk1?	MWXTRW5ITVJ?
RERF-LC-MS	NGPO[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTF{ND6zNUBvVQ>?	Mn3XV2FPT0WU
DMS-114	NUjJSWdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorQTWM2OD1zMkWuNFkhdk1?	NH60e3JUSU6JRWK=
HuP-T4	Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTF{Nj65O{BvVQ>?	MnHUV2FPT0WU
HCC2157	MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXpdFZnUUN3ME2xNlcvPSCwTR?=	M1zXNnNCVkeHUh?=
SKG-IIIa	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XDPWlEPTB;MUK4Mlghdk1?	Mn;qV2FPT0WU
HCT-116	M{PoU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF\|MD62OEBvVQ>?	MVvTRW5ITVJ?
BB30-HNC	NVOwXnJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF\|MD63PEBvVQ>?	M3LqTnNCVkeHUh?=
KYSE-270	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr2XYZKSzVyPUGzNE45QCCwTR?=	M33qbXNCVkeHUh?=
MFM-223	Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PjO2lEPTB;MUOxMlUyKG6P	NUnPT2xDW0GQR1XS
NH-12	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TLNmlEPTB;MUOyMlk6KG6P	MUjTRW5ITVJ?
U-118-MG	NXOxcGhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFS5eVdKSzVyPUGzN{43OiCwTR?=	NYDZOIZ7W0GQR1XS
ESS-1	NXq3TmlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2ezeGlEPTB;MUO1MlE5KG6P	MX\TRW5ITVJ?
D-247MG	NY\Lb4NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rYbGlEPTB;MUO1MlIyKG6P	NVi4foR2W0GQR1XS
IGROV-1	M2K2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTF\|NT63OkBvVQ>?	NIfGcodUSU6JRWK=
C-33-A	M3XCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmf6TWM2OD1zM{WuPVchdk1?	MXXTRW5ITVJ?
NCI-H1693	M4PjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonLTWM2OD1zM{[uNVIhdk1?	MkC2V2FPT0WU
MLMA	M{PuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTF\|Nj61PEBvVQ>?	M2rQeXNCVkeHUh?=
SK-N-AS	MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XqXGlEPTB;MUO3MlE4KG6P	M2f2cHNCVkeHUh?=
NCI-H1755	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTF\|OD64OUBvVQ>?	M3j0XHNCVkeHUh?=
CHP-134	NWXzSmg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\xTWM2OD1zM{muOVUhdk1?	NEe3[XhUSU6JRWK=
LS-513	NEHZNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTF2MD65NUBxVQ>?	M2jyWHNCVkeHUh?=
TE-12	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLXXVVKSzVyPUG0NE46OyCwTR?=	MnfZV2FPT0WU
KNS-42	NVrrTVdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTF2ND6zJI5O	NEHZS3JUSU6JRWK=
SJRH30	M1K4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vvWmlEPTB;MUS0MlQ1KG6P	Mly3V2FPT0WU
NCI-H1092	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nUNWlEPTB;MUS0MlUzKG6P	NVXyeVZyW0GQR1XS
H-EMC-SS	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnPcnBtUUN3ME2xOFYvQDFibl2=	NGXSOVFUSU6JRWK=
SK-MEL-3	M3fodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnm5TWM2OD1zNEeuOVUhdk1?	M3\sbHNCVkeHUh?=
SK-N-FI	M4fa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjLbmJ1UUN3ME2xOFcvPTlibl2=	NHKzXohUSU6JRWK=
NCI-H2126	NXXUO2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYD6cVJvUUN3ME2xOFgvOTVibl2=	MkniV2FPT0WU
NCI-H1299	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LCSWlEPTB;MUWwMlIzKG6P	M2LEWHNCVkeHUh?=
CFPAC-1	NYLSWpN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfnUYhKSzVyPUG1NE43PiCwTR?=	NXuwTno4W0GQR1XS
NCI-H661	M{T2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTF3MT6yOkBvVQ>?	NEPzbHdUSU6JRWK=
KYSE-70	NGf3e2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTF3MT63PUBvVQ>?	NHTleHpUSU6JRWK=
SW900	NVPMN\|FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTF3ND62OUBvVQ>?	MUPTRW5ITVJ?
Ca-Ski	NGf2TFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF3Nj6zPUBvVQ>?	NHLaUJpUSU6JRWK=
HPAF-II	M3\JO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfQTWM2OD1zNU[uOFchdk1?	Mom4V2FPT0WU
LB2518-MEL	M{Ps[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XDXWlEPTB;MUW3MlEhdk1?	MmrOV2FPT0WU
LC-2-ad	NG\VTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWK4bnVUUUN3ME2xOVgvPjJibl2=	MkTqV2FPT0WU
HCC1806	MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlryTWM2OD1zNkeuPFghdk1?	NInzVZZUSU6JRWK=
UACC-62	NFfBbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEX0eJRKSzVyPUG2PE4xQSCwTR?=	NV;OSIFYW0GQR1XS
KM-H2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTF5MD61PEBvVQ>?	MYnTRW5ITVJ?
NCI-H2347	NV6xd4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XJc2lEPTB;MUeyMlczKG6P	MlPIV2FPT0WU
SCC-15	MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnP5TWM2OD1zN{OuOlYhdk1?	NHzkVlhUSU6JRWK=
BB49-HNC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vWXWlEPTB;MUezMlgyKG6P	MkTzV2FPT0WU
GMS-10	NFfEfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHJWVM1UUN3ME2xO\|MvQTRibl2=	M{jScXNCVkeHUh?=
NCI-H2052	NIHuT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3HVWtoUUN3ME2xO\|QvQSCwTR?=	MmKxV2FPT0WU
SW626	M1rPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjaXGd3UUN3ME2xO\|YvODZibl2=	M{[2d3NCVkeHUh?=
MDA-MB-415	M{nxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTF5Nj62NUBvVQ>?	M130T3NCVkeHUh?=
Saos-2	NXPaW21YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nM[WlEPTB;MUe5MlM2KG6P	NIOwbYdUSU6JRWK=
DK-MG	MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTF6MD6zJI5O	NIfoeIVUSU6JRWK=
SNU-C2B	M3fZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfL[pduUUN3ME2xPFAvPzNibl2=	MVTTRW5ITVJ?
A427	NEjzTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzVV4VJUUN3ME2xPFIvPTdibl2=	MonRV2FPT0WU
KP-N-YS	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TyOGlEPTB;MUi1JI5O	MYXTRW5ITVJ?
J82	NXvZXFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoexTWM2OD1zOEWuNVghdk1?	Mlr0V2FPT0WU
LS-411N	NW[2e3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPsZYJIUUN3ME2xPFcvOjhibl2=	NEjvVW5USU6JRWK=
HCC1937	NV7kbFRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnUPFFuUUN3ME2xPFcvPDlibl2=	NI[1[29USU6JRWK=
OE33	NIO0O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWT1eoNGUUN3ME2xPFgvQTdibl2=	M1\IfHNCVkeHUh?=
NB7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\VT2lEPTB;MUi5Mlg6KG6P	MXnTRW5ITVJ?
SW684	M3G4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L6cmlEPTB;MUm2MlE{KG6P	NYfRb2dSW0GQR1XS
HT-144	M2jWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmP1TWM2OD1zOU[uNVUhdk1?	NHO1cYRUSU6JRWK=
SK-MEL-30	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDaTWM2OD1zOU[uNkBvVQ>?	M{WzW3NCVkeHUh?=
DBTRG-05MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYm1RolVUUN3ME2xPVgvPDdibl2=	MUjTRW5ITVJ?
NCI-H1395	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfIRotKSzVyPUG5PE45PSCwTR?=	NWHkXZQ2W0GQR1XS
NCI-H2122	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\BTWM2OD1{MECuOVkhdk1?	M2TqTXNCVkeHUh?=
no-10	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm2fo5kUUN3ME2yNFEvODRibl2=	NHvFT5dUSU6JRWK=
SW48	NW\vRld3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTJyMT6zNUBvVQ>?	MWLTRW5ITVJ?
NCI-H1650	MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\remxKSzVyPUKwOE4xOSCwTR?=	NUnEbm1NW0GQR1XS
MZ1-PC	M1L6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYC5OHpMUUN3ME2yNFUvPThibl2=	MnrpV2FPT0WU
U-266	NYmwOHhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJyNT63PUBvVQ>?	MnfaV2FPT0WU
CAS-1	NEj1NVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPtZVQyUUN3ME2yNFcvPDRibl2=	NVzxboJbW0GQR1XS
AU565	NHzzVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjHTWM2OD1{MUKuPFIhdk1?	NUPvelRmW0GQR1XS
UACC-257	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\1SFNiUUN3ME2yNVMvQTlibl2=	NXniSmxrW0GQR1XS
CAL-27	NV3mV3F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYntSWF7UUN3ME2yNVcvODVibl2=	Mn;zV2FPT0WU
NCI-H23	M1v6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTrWmdtUUN3ME2yNVkvOzNibl2=	MmDiV2FPT0WU
TE-6	NGrmS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTJzOT62PEBvVQ>?	MXvTRW5ITVJ?
TGBC24TKB	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJ{Mj6xO{BvVQ>?	NGr6c3NUSU6JRWK=
TE-1	M4LWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3KwUGlEPTB;MkKyMlg5KG6P	NGXEVIhUSU6JRWK=
RCC10RGB	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHsTWM2OD1{MkSuNVkhdk1?	MVzTRW5ITVJ?
NCI-H596	M2LuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJ{OD6yNkBvVQ>?	NHS2XYRUSU6JRWK=
SW954	NHXofFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITwXpVKSzVyPUKzN{45OyCwTR?=	NEjVcHhUSU6JRWK=
NCI-H2087	M1u4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fL[2lEPTB;MkO0MlUyKG6P	NFGyZ\|RUSU6JRWK=
SK-PN-DW	NXLDe2dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIH4[GxKSzVyPUKzOU4yQSCwTR?=	NUDXS446W0GQR1XS
KM12	NFP2fJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXGTWM2OD1{M{WuO{BvVQ>?	MlHzV2FPT0WU
BT-474	NFv4VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTJ\|NT63N{BvVQ>?	M{jKWHNCVkeHUh?=
IST-MES1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHIO2lKSzVyPUKzOk42PyCwTR?=	NF3qSFFUSU6JRWK=
HT-1197	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfRU25KSzVyPUKzPE4xQSCwTR?=	MkLPV2FPT0WU
CAL-54	NWTQbGdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDtcotKSzVyPUKzPE41QSCwTR?=	NVXld21lW0GQR1XS
NB10	NXm0VmN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzsc\|JKSzVyPUK0NE4xPiCwTR?=	M2HTU3NCVkeHUh?=
PANC-10-05	NFv1cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\PNWlEPTB;MkS1MlU3KG6P	NYjQTFkzW0GQR1XS
NCI-H522	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJ2OD6zNUBvVQ>?	NV:wOHBnW0GQR1XS
A388	NHf0OVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTJ2OT64NkBvVQ>?	MlXmV2FPT0WU
GOTO	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7sTWM2OD1{NUCuNlkhdk1?	Mmr4V2FPT0WU
KLE	M4HYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33tPWlEPTB;MkWxMlg4KG6P	MlfuV2FPT0WU
KYSE-520	NYfHTnhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTJ3Mj64OkBvVQ>?	NGrmW2ZUSU6JRWK=
HCE-4	NUX0RZRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH64XHBKSzVyPUK2Nk42KG6P	MWrTRW5ITVJ?
KURAMOCHI	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\GOnB5UUN3ME2yOlUvQSCwTR?=	Mn[2V2FPT0WU
HCC38	M3K2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4i1XmlEPTB;Mk[2MlQ5KG6P	Mn3yV2FPT0WU
FADU	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDpT3FKSzVyPUK2Ok43OyCwTR?=	MX7TRW5ITVJ?
CW-2	NFThdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1q0VmlEPTB;Mk[5Mlk3KG6P	M{nlNnNCVkeHUh?=
L-428	NF3GTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTJ5NT6xOUBvVQ>?	NUe2SXY5W0GQR1XS
HCC1569	NGXNZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWD6UJF{UUN3ME2yO\|UvQDRibl2=	M4iyOnNCVkeHUh?=
NCI-H810	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnOTWM2OD1{N{iuN\|Ehdk1?	M1vxXHNCVkeHUh?=
LB771-HNC	NHvoOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\V[2FiUUN3ME2yPFUvQDRibl2=	MUXTRW5ITVJ?
LCLC-103H	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1r0emlEPTB;Mki1Mlk6KG6P	MX3TRW5ITVJ?
EFO-21	M3nwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7RUXNpUUN3ME2yPFcvPjhibl2=	NVi5flBbW0GQR1XS
CAL-72	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;ZPW5vUUN3ME2yPVMvOTlibl2=	NYHyXZBrW0GQR1XS
SCC-9	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnV[phmUUN3ME2yPVMvOjJibl2=	MWTTRW5ITVJ?
COLO-829	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7pTWM2OD1{OU[uOUBvVQ>?	MVzTRW5ITVJ?
U-87-MG	NWrZfG8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTNyMD63N{BvVQ>?	NYDYNpRxW0GQR1XS
MZ7-mel	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7nTWM2OD1\|MkOuO\|Yhdk1?	NHPLNFBUSU6JRWK=
NCI-H1770	MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTiTWM2OD1\|Mk[uO\|Qhdk1?	NWKwN4JCW0GQR1XS
ChaGo-K-1	NWDKZlZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\5PZVKSzVyPUOyPE4yKG6P	NFS1fItUSU6JRWK=
SiHa	M1LrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDR[\|BKSzVyPUOyPU4zPCCwTR?=	NH3FR2dUSU6JRWK=
NCI-SNU-5	M2P1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTMWHlKSzVyPUOzOk44PyCwTR?=	M2rvO3NCVkeHUh?=
DJM-1	NX7hcZA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\uXJRKSzVyPUO0NE4{OyCwTR?=	MXnTRW5ITVJ?
OE19	M3Wyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF6xVYZKSzVyPUO0NE42OyCwTR?=	MnW0V2FPT0WU
NCI-H1651	M3TlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvkTXZKSzVyPUO0OE4yQCCwTR?=	NIHXTGhUSU6JRWK=
COLO-792	NFHyPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrGTWM2OD1\|NUSuOFIhdk1?	NXHvXFNvW0GQR1XS
ACHN	NWq0VZJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnBfHZzUUN3ME2zOVYvPzFibl2=	MknDV2FPT0WU
TH-3	NFz4THFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTN5OT65OUBvVQ>?	Mn36V2FPT0WU
HT-1376	NHvqU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzLfHlKSzVyPUO4OE45QCCwTR?=	M{L0NHNCVkeHUh?=
RH-18	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTEeI5ZUUN3ME2zPVQvPzRibl2=	MoLrV2FPT0WU
NB6	NVLIRXhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTN7Nj62OkBvVQ>?	NHzhN41USU6JRWK=
COLO-320-HSR	M4PuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLOW4lKSzVyPUSwN{4{PyCwTR?=	M2X0dXNCVkeHUh?=
UACC-893	NV3iZ3NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELDOo1KSzVyPUSwOk41PyCwTR?=	MmHrV2FPT0WU
DSH1	NUK1TGNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFP0bY5KSzVyPUSwOk46OSCwTR?=	NEnZ[oJUSU6JRWK=
TE-10	NVLycIZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jsfWlEPTB;NEC3MlAyKG6P	NXXwVHJCW0GQR1XS
HCC70	M{TzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkGxTWM2OD12MEmuNlEhdk1?	M3z4b3NCVkeHUh?=
TGBC11TKB	NEmxTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7mTWM2OD12MUCuN\|Mhdk1?	NVP5bmo6W0GQR1XS
NCI-H727	MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTRzMj6xNUBvVQ>?	MXfTRW5ITVJ?
ALL-PO	NHmweVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjRcmVKSzVyPUSxOU43QSCwTR?=	MmPZV2FPT0WU
ABC-1	Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HPWGlEPTB;NEKwMlQ2KG6P	MkG5V2FPT0WU
NCI-H69	MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFztSnJKSzVyPUSyOk44PiCwTR?=	MmP3V2FPT0WU
GP5d	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jBc2lEPTB;NEO0MlQyKG6P	MYjTRW5ITVJ?
UMC-11	NHrDc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7MN5RrUUN3ME20OVgvOzZibl2=	MWrTRW5ITVJ?
RMG-I	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHtTWM2OD12NkeuOVYhdk1?	Mo\uV2FPT0WU
YAPC	NELIUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfVe2JKSzVyPUS5NE43KG6P	MWjTRW5ITVJ?
LS-1034	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTR7MT6wOkBvVQ>?	NXvQRW1rW0GQR1XS
RCM-1	NFXue\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLZTWM2OD12OU[uOlghdk1?	NWjiZXhzW0GQR1XS
HCC1954	NXL6N5NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTVzMj61JI5O	M{nRS3NCVkeHUh?=
SK-MEL-24	NH;GRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTVzNj61NUBvVQ>?	MlTTV2FPT0WU
NB12	NXTzPJluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHwNmNKSzVyPUWyPE41OiCwTR?=	NHPVSlBUSU6JRWK=
SW756	M2rzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkCyTWM2OD13NUSuPVYhdk1?	NIPid4xUSU6JRWK=
HCC1187	M{fZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTV5NT64N{BvVQ>?	M1W4NHNCVkeHUh?=
NCI-H2342	M2DjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHOfXBKSzVyPUW5NE4{QSCwTR?=	NVTSb\|FqW0GQR1XS
NCI-H2291	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXLTWM2OD13OUiuN\|Ehdk1?	M2DYcHNCVkeHUh?=
OVCAR-3	M1PTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTV7OD65OkBvVQ>?	NWrrcJBPW0GQR1XS
MHH-NB-11	NIm5flhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPIc\|Z1UUN3ME22NlkvODFibl2=	NIH5XJFUSU6JRWK=
SAS	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XFfWlEPTB;NkWyMlY4KG6P	MkXOV2FPT0WU
COLO-824	M{S3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTZ6OT6zO{BvVQ>?	MlfOV2FPT0WU
HCC1395	NHrFbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3WzT2lEPTB;Nkm4MlUhdk1?	NGXGN2tUSU6JRWK=
COLO-668	NEn1UZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTdyNj6xJI5O	M2D5enNCVkeHUh?=
NCI-H226	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\nWVRKSzVyPUewO{45KG6P	NUPlc5dWW0GQR1XS
NB17	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnMZYd5UUN3ME23NlEvPzVibl2=	M3T4N3NCVkeHUh?=
SW1463	M3vkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHmXY1LUUN3ME23N\|kvOTlibl2=	NH;KTlRUSU6JRWK=
TGW	NWHGclNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTd4MD6xOUBvVQ>?	NYrNTmVpW0GQR1XS
NCI-H526	NGnH[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTh{Mz61N{BvVQ>?	Mn\3V2FPT0WU
COR-L88	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEW1dJJKSzVyPUi0PE4yOiCwTR?=	NVTjWmE3W0GQR1XS
NCI-H441	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\mTWM2OD16OUWuNlIhdk1?	M3PhZ3NCVkeHUh?=
NCI-H630	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLUdY5KSzVyPUmxNk46PiCwTR?=	Mly5V2FPT0WU
Mo-T	NH7JWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PHU2lEPTB;OUS3Mlg5KG6P	NXLC[nZRW0GQR1XS
JAR	M2iy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LwOmlEPTB;OUW2MlI1KG6P	NHPNZlBUSU6JRWK=
NCI-H1838	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUm2e3UxUUN3ME2xMlAzOzh6IN88US=>	NEXqZ\|NUSU6JRWK=
DoTc2-4510	NEGyWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmCwTWM2OD1zLkC3N\|c3KM7:TR?=	MlqyV2FPT0WU
MKN28	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TFS2lEPTB;MT6wPVAzPCEQvF2=	NV:0bpBiW0GQR1XS
HuP-T3	M{jhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXvT3JKSzVyPUGuNVE6ODVizszN	MnH6V2FPT0WU
TE-9	NVTZTHpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV24RVN{UUN3ME2xMlEzQTd\|IN88US=>	M3XDXXNCVkeHUh?=
NY	M1XwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HicGlEPTB;MT6xOlc6OiEQvF2=	MUfTRW5ITVJ?
HT55	NFuzbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PQVGlEPTB;MT6zNVM1PCEQvF2=	M4TrdnNCVkeHUh?=
SW837	M3rCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3XTWM2OD1zLkOyPVc5KM7:TR?=	M2O4SHNCVkeHUh?=
NCI-H2029	NGHqXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrjVpZ3UUN3ME2xMlQyPzlzIN88US=>	M4XNTHNCVkeHUh?=
IST-SL1	NVvUVoRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTFwNESyOEDPxE1?	M2LCeXNCVkeHUh?=
COLO-741	MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XLXWlEPTB;MT60PVc4OSEQvF2=	NVPXOpgzW0GQR1XS
LU-65	NF[zXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfUfXdpUUN3ME2xMlYzOjR7IN88US=>	Mn7tV2FPT0WU
NCI-H1304	NGP2ZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTFwNkW0PVgh\|ryP	M2PPcXNCVkeHUh?=
KARPAS-299	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHQTWM2OD1zLke5OFc6KM7:TR?=	M3L1bHNCVkeHUh?=
NCI-H358	NXHuWGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jYXGlEPTB;MT65OVUxOyEQvF2=	MnLuV2FPT0WU
OAW-28	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLTTWM2OD1{LkC2PVE6KM7:TR?=	NFXoc5RUSU6JRWK=
C8166	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLEU4R3UUN3ME2yMlY{Ozl{IN88US=>	MYTTRW5ITVJ?
COLO-678	M1\JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDBXGNKSzVyPUKuPFM4PjhizszN	NFX5e21USU6JRWK=
SK-N-DZ	NEj0W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPkTWM2OD1{Lki2N\|gyKM7:TR?=	MXXTRW5ITVJ?
NCI-H82	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHiSGNKSzVyPUKuPVA{PjlizszN	MmXZV2FPT0WU
JVM-2	M2CzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NID1ZoJKSzVyPUOuNFMyQDhizszN	MVvTRW5ITVJ?
SW1116	NEj1OIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXOSJVKSzVyPUOuNFU1OTFizszN	MXLTRW5ITVJ?
MDA-MB-453	NG\BZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLodmFKSzVyPUOuNVA1OzlizszN	NV3JTZpTW0GQR1XS
Calu-6	M{L4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rTemlEPTB;Mz6xPVk4KM7:TR?=	NYT3[JZCW0GQR1XS
SHP-77	NY[xPZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPWTWM2OD1\|LkWyPEDPxE1?	M37CUXNCVkeHUh?=
Capan-2	MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTRwM{K1PFEh\|ryP	NF61Um5USU6JRWK=
SW948	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[yRm9XUUN3ME20Mlc1Pzd7IN88US=>	MWfTRW5ITVJ?
HDLM-2	NX\ZXHpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTZcZNKSzVyPUWuNFc4OjVizszN	M1nOOXNCVkeHUh?=
LAN-6	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLmSW55UUN3ME22MlIyPDl3IN88US=>	NV;xS\|dwW0GQR1XS
LU-135	NEjENm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTZwNEOwO\|ch\|ryP	M2TZNnNCVkeHUh?=
T84	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4ezZ2lEPTB;Nj65PFY1KM7:TR?=	NX\1VndtW0GQR1XS
CAPAN-1	M2[4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTdwNkKyN\|Mh\|ryP	MXfTRW5ITVJ?
SW1417	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVToc3ZyUUN3ME23MlkyPzNzIN88US=>	MYPTRW5ITVJ?
BALL-1	NFi0em9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRThwNUC0NFkh\|ryP	MoD1V2FPT0WU
HT-29	M2DvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTlwMEe1PVkh\|ryP	MoHkV2FPT0WU
C3A	M1vNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvqS2JEUUN3ME25Mlg5Ozl2IN88US=>	MnnPV2FPT0WU
NCI-H1993	NELqUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zGV2lEPTB;MUCuOVA5OSEQvF2=	MV\TRW5ITVJ?
SK-MEL-1	NHvwemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13GZmlEPTB;MUGuOlI5QSEQvF2=	Mk\mV2FPT0WU
DU-145	NIjxRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M121b2lEPTB;MUSuOVA2OiEQvF2=	M4K5[nNCVkeHUh?=
KP-N-YN	NUixUYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGSzXWpKSzVyPUG0MlUyODNizszN	NFG0OHhUSU6JRWK=
CCRF-CEM	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HHOGlEPTB;MUSuO\|gxQSEQvF2=	MV7TRW5ITVJ?
ZR-75-30	NFXPUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nMPWlEPTB;MU[uN\|MxOyEQvF2=	NVS0eZN6W0GQR1XS
A673	M2DpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XTVGlEPTB;MkCuOVUxPyEQvF2=	NFfwVnJUSU6JRWK=
K-562	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvXfm56UUN3ME2yPE41OTh\|IN88US=>	MYrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-BEZ235
Smiles	CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235)